"Advancing obesity and obesity-related trials with patients at the center of development.
LEARN MORE
Reimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.
Research & Development Overview
Generate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.
REAL WORLD EVIDENCE OVERVIEW
Elevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.
COMMERCIALIZATION OVERVIEW
Orchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.
COMPLIANCE OVERVIEW
When your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.
TECHNOLOGIES OVERVIEWExplore our library of insights, thought leadership, and the latest topics & trends in healthcare.
DISCOVER INSIGHTSAn in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.
SEE LATEST REPORTS
By making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.
LEARN MORE
Building on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.
LEARN MORE
Your new expert analyst is here. Be at the forefront of data-driven decision-making with a new generative AI tool that enables you to interact with our products and solutions like never before. Get results you can trust, faster.
LEARN MORE
The IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.
LEARN MORE
The IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.
LEARN MORE
IQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.
LEARN MORE
Empowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm.
LEARN MORE
"At IQVIA your potential has no limits. We thrive on bold ideas and fearless innovation. Join us in reimagining what’s possible.
VIEW ROLESThis report provides analysis around a key aspect of medicine spending growth trends: manufacturer net revenues. It draws on previously published analysis in our reports Medicines Use and Spending in the U.S.: A Review of 2016 and Outlook to 2021 (April 2017) and Outlook for Global Medicines Through 2021: Balancing Cost and Value (Dec 2017).
Recent reports of increases in drug list prices and overall spend on medicines have put the spotlight on the cost of medicines in the U.S. The increasing list prices of specific medicines has, in particular, generated significant media attention. These messages have amplified concerns of policy makers, insurers, pharmacy benefit managers and other healthcare stakeholders that drug prices are to blame for rising costs in the U.S. healthcare system.
However, much of the coverage on list prices has left out the more complex context of the prices, including
In this report you will find an in-depth analysis of the trends in medicine spending growth and manufacturer net revenues suggesting a far more complex situation than one of prices set by manufacturers simply being too high or growing too fast.
In particular the report highlights the dynamics between prices and volume and introduces a novel way of combining market segments to consider the impact of patent expiry alongside other price related elements. The result is a clearer reflection of trends that affect the costs of medicines in the market. The report also notes that the trend of manufacturer revenues and patient costs are evolving in opposing directions, and that patient exposure to cost trends are not uniformly distributed across patients.
Learn how IQVIA is unlocking genomic data, at scale, while preserving privacy. Enabling a faster, more flexible, and less expensive approach for scientific enquiry into human biology, drug discovery and drug development.
IQVIA is using vast quantities of data in powerful new ways. See how we can help you tap into information from past trials, patient reported outcomes and other sources to accelerate your research.
